Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @EMcCallister01
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @EMcCallister01
-
Erin McCallister proslijedio/la je Tweet
$PFE's Bourla aims for BD over buybacks and remains commited to at least a 6% CAGR over the next five yearshttps://buff.ly/3aJnhjgHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
After nearly 12 years, tomorrow is my last day with
@BioCentury. I am joining PwC's Health Research Institute next month. It's been an amazing ride and I am looking forward to the next adventure. Give@Laurenmmartz a follow to stay up to date on Clin Dev. Cheers!Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
Biocentury articles are really top notch
#Cart#celltherapy landscapes with target antigenspic.twitter.com/LeXQCG2hBT
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
Want to know who’s doing what to get CAR Ts to solid tumors? Winnie Pong has sliced and diced the data in
@BioCentury. Take-home message: the majority are going after non-validated targets. Less of the lemming factor than in other areas of IO.https://www.biocentury.com/biocentury/targets-mechanisms/2020-01-24/targets-and-indications-car-t-developers-are-exploring--0 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
Publication of the gene sequence of the Wuhan coronavirus has sparked a race to develop vaccines and drugs. The first could be monoclonal antibodies that are both treatment and prophylaxis. https://www.biocentury.com/biocentury/product-development/2020-01-24/coronavirus-outbreak-creating-testbed-new-vaccine-and- …pic.twitter.com/KbyHRdh7GV
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Great piece from
@LaboratoryLiz on recent manufacturing moves, including Deerfield's new CDMO. Manufacturing is a BIG deal in cell and gene therapy btwhttps://www.biocentury.com/biocentury/tools-techniques/2020-01-24/biotechs-academics-turn-partnerships-overcome-manufacturing- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
Roche is looking to make CNS a growth driver to match oncology this next decade. Partnering with small and large companies will be a big part of that.https://buff.ly/2S0yHqz
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
Some biotechs are turning to partnerships to increase gene and cell therapy manufacturing capacity. January saw at least seven manufacturing deals and launches, including a new CDMO from Deerfield and a JV from
$TECH$FRE and Wilson Wolfhttps://buff.ly/2TUaGUvHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
Here's a round-up of 3 interesting preclinical discoveries, via
@BioCentury. Research from@institut_curie#INSERM@NIH#TeneoBio#Basilea$BSLN. Targets: 4-IBB, alpha-SMA, BCMA, CXCL12, FAP and more.https://www.biocentury.com/bc-extra/preclinical-news/2020-01-23/jan-23-preclinical-quick-takes-metastasis-associated-cancer- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
Guest Commentary: EMD Serono and Accelerated Cure Project argue a new, more collaborative model is needed to effectively integrate the patient voice into R&Dhttps://buff.ly/3aF89mV
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
An oral spinal muscular atrophy (
#SMA) could give patients/parents/physicians another option. If efficacy is good and it is less expensive, will payers push parents to select risdiplam over Zolgensma, a potential cure? Will Biogen respond by cutting the price of Spinraza?https://twitter.com/BioCentury/status/1220436143172395011 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
Great article from
@BioCentury@LaurenMMartz on developments in manufacturing, yields, targeting and dosing needed take gene therapy to next level
https://twitter.com/BioCentury/status/1218405155076476929 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
Really interesting article
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
Good read from my colleague
@li_hongjiang -> 4 big pharma companies won bids for five off-patent products, taking an average price cut of 82%...https://twitter.com/BioCentury/status/1220156774478684160 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
Moderna, Novavax among biotechs working on Wuhan virus -- but vaccine at least a year outhttps://www.biocentury.com/bc-extra/preclinical-news/2020-01-21/moderna-novavax-among-biotechs-working-wuhan-virus-vaccine- …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
.
@EPOorg decision strengthens UC’s#CRISPR patent position in Europe over Broad -- ensuring that the CRISPR IP landscape is going to look much different in Europe than the U.S.@BioCentury's@Laurenmmartz explainshttps://www.biocentury.com/bc-extra/tools-techniques/2020-01-17/epo-decision-strengthens-uc%E2%80%99s-crispr-patent-position-europe- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
@EMcCallister01 reminds us companies are only one part of a big system. It’s not just about lower list prices.#JPM20#biotechshowcaseHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
#CFIUS crashes#JPM2020 party as Treasury final rules scale back definition of genetic data that could trigger review of foreign investments in U.S. companies that collect genetic information.@BioCentury's@steveusdin1 explains:https://www.biocentury.com/bc-extra/politics-policy/2020-01-13/treasury-narrows-definition-genetic-data-cfius-reviews …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Erin McCallister proslijedio/la je Tweet
$MOR deal underwhelms investors who appear to question choice of$INCY as partner but $900M upfront is 2nd largest in past year for an EU biotech. via@BioCentury's@StephenPHansenhttps://www.biocentury.com/bc-extra/company-news/2020-01-13/morphosys-nets-900m-front-global-deal-incyte-anti-cd19-mab …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Newco from Borisy, Nallicheri,
@peterbachmd and Horning will dev, launch innovative drugs at radically lower prices, and they'll work with other stakeholders in the system to help make sure those those cheaper drugs get used, bring down costshttps://www.biocentury.com/biocentury/emerging-company-profile/2020-01-12/eqrx-launches-200m-plans-offer-cheaper-equally-good- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.